Clinical Trial Update: Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Ulixertinib (BVD-523) in cancers with targeted genetic alterations under MATCH Subprotocol Z1L; the study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma

Drugs mentioned

• Ulixertinib (ulixertinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING